Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

M.P. Kolinsky,P. Rescigno,D. Bianchini,Z. Zafeiriou,N. Mehra,J. Mateo,V. Michalarea,R. Riisnaes,M. Crespo,I. Figueiredo,S. Miranda,D. Nava Rodrigues,P. Flohr,N. Tunariu,U. Banerji,R. Ruddle,A. Sharp,J. Welti,M. Lambros,S. Carreira

Annals of Oncology（2020）

Cited 56|Views115
No score
Abstract
•Preclinical data suggest that inhibition of both the AR and PI3K/AKT/mTOR signalling has synergistic activity in PTEN loss prostate cancer models.•Here we present a phase I clinical trial of enzalutamide combined with the AKT inhibitor capivasertib in patients with mCRPC and show that this regimen is safe and tolerable.•This combination has antitumour activity with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway.
More
Translated text
Key words
prostate cancer,AZD5363,capivasertib,AKT inhibitor,enzalutamide,biomarkers
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined